Recent News for ODT - Odonate Therapeutics, Inc.

Date Title
Jun 8 Play the Best Sector of Summer With These ETFs & Stocks
Jun 6 Can The Uptrend Continue for Odonate Therapeutics (ODT)?
Jun 5 New Research: Key Drivers of Growth for Helen of Troy, Macro Bank, American Software, Shire plc, KB Financial Group, and Odonate Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
Jun 4 The Week Ahead: Apple's Developer Conference In The Spotlight, ASCO Meeting Could Move Biotechs
Jun 2 Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer
Jun 2 Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.
May 31 Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
May 16 Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 3 Odonate Therapeutics beats by $0.18
May 3 Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018
Apr 10 Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of Growth
Mar 22 Midday Gainers / Losers (03/22/2018)
Mar 15 Report: Developing Opportunities within Odonate Therapeutics, Greenlight Reinsurance, Landmark Infrastructure Partners LP, GTx, First Mid-Illinois Bancshares, and iClick Interactive Asia Group — Future Expectations, Projections Moving into 2018
Mar 3 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $385,251 of Shares
Feb 28 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $784,541 of Shares
Feb 23 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.1 million of Shares
Feb 14 Odonate Therapeutics misses by $0.14
Feb 14 Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017
Jan 5 Goldman bullish on biopharma in 2018
Jan 2 Goldman Sachs: Odonate Therapeutics Has Potential, But There's Greater Upside Elsewhere
Jan 2 Premarket analyst action - healthcare
Dec 30 Stocks to watch next week
Dec 28 Odonate Therapeutics initiates Phase 3 trial for tesetaxel
Dec 28 Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer
Dec 18 Disrupting Breast Cancer Paradigms - Odonate Therapeutics

Back to the Main ODT Page...